




Instance: composition-en-3552692c711f8f7419edb391c717f809
InstanceOf: CompositionUvEpi
Title: "Composition for brineura Package Leaflet"
Description:  "Composition for brineura Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp3552692c711f8f7419edb391c717f809)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - brineura"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Brineura is and what it is used for </li>
<li>What you need to know before you or your child is given Brineura </li>
<li>How Brineura is given </li>
<li>Possible side effects </li>
<li>How to store Brineura </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What brineura is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What brineura is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brineura contains the active substance cerliponase alfa, which belongs to a group of medicines known 
as enzyme replacement therapies. It is used to treat patients with neuronal ceroid lipofuscinosis type 2 
(CLN2) disease, also known as tripeptidyl peptidase-1 (TPP1) deficiency. </p>
<p>People with CLN2 disease do not have any enzyme called TPP1 or they have too little of it and this 
causes a build-up of substances called lysosomal storage materials. In people with CLN2 disease, 
these materials build-up in certain parts of the body, mainly the brain. </p>
<p>How Brineura works 
This medicine replaces the missing enzyme, TPP1, which minimises the build-up of the lysosomal 
storage materials. This medicine works to slow the progression of the disease.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take brineura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take brineura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You must not receive Brineura<br />
- If you or your child has had life-threatening allergic reactions to cerliponase alfa or any of the 
other ingredients of this medicine (listed in section 6), and the reactions continue to happen 
when cerliponse alfa is given again. 
- If you or your child has a device implanted to drain extra fluid from the brain. 
- If you or your child currently has signs of a device infection or problems with the device. Your 
doctor may decide to continue treatment once the device infection or problems are resolved.  </p>
<p>Warnings and precautions<br />
Talk to your doctor before you or your child is given Brineura. 
- You or your child may get problems with the implanted device used during treatment with 
Brineura (see section 4  Possible side effects ), including infection or a fault in the device. 
Signs that you or your child may have an infection include fever, headache, neck stiffness, light 
sensitivity, nausea, vomiting, and change in mental status. Signs of problems with the device </p>
<p>include swelling, redness of the scalp, fluid leaking from device and bulging of the scalp. 
Treatment may be interrupted if the device needs to be replaced or until the infection clears. 
Within 4 years of use, the access device may need to be replaced and will be determined by 
your doctor. Talk to your doctor if you have any questions about your device.<br />
- Life-threatening allergic reactions (anaphylactic reactions) are possible with this medicine. Your 
doctor will monitor you or your child for symptoms of life threatening allergic reactions, such 
as hives, itching or flushing, swollen lips, tongue, and/or throat, chills, accelerated heart rhythm, 
shortness of breath, hoarseness, turning blue around finger tips or lips, low muscle tone, 
fainting, diarrhoea or incontinence. Seek immediate medical care should these symptoms occur. 
- Your doctor will check your or your child s heart rate, blood pressure, respiratory rate, and 
temperature before, during, and after treatment. The doctor may decide on additional monitoring 
if it is needed. 
- Your doctor will check for abnormal heart electrical activities (ECG) every 6 months. If you or 
your child has a history of heart problems, your doctor or nurse will monitor your heart activity 
during each infusion. 
- Your doctor may send samples of brain fluid to check for signs of infection. 
- This medicine has not been given to patients with advanced disease at the start of treatment or in 
children younger than 1 year of age. Your doctor will discuss whether Brineura treatment is 
right for you or your child. </p>
<p>Other medicines and Brineura 
Tell your doctor if you or your child is taking, has recently taken, or might take any other medicines. </p>
<p>Pregnancy, breast-feeding and fertility<br />
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before treatment with this medicine. </p>
<p>You should not receive this medicine during pregnancy unless clearly necessary. It is not known if this 
medicine can harm your unborn baby. </p>
<p>You should not receive this medicine if you are breast-feeding. It is not known if this medicine passes 
into human breast milk. </p>
<p>It is not known if this medicine impacts human fertility. </p>
<p>Driving and using machines<br />
It is not known if this medicine will impact the ability to drive or use machines. Please consult your 
doctor.  </p>
<p>Brineura contains sodiumand potassium<br />
This medicine contains 17.4 mg sodium (main component of cooking/table salt) in each vial. This is 
equivalent to 0.87% of the recommended maximum daily dietary intake of sodium for an adult. </p>
<p>This medicine contains potassium, less than 1 mmol (39 mg) per vial, that is to say essentially 
 potassium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take brineura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take brineura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You or your child will need to have surgery to implant the device for giving this medicine. The device 
helps the medicine to reach a specific part of the brain. </p>
<p>This medicine will be given by a doctor with knowledge of giving medicines by 
intracerebroventricular use (infusion into the fluid of the brain) in a hospital or clinic. </p>
<p>This medicine has not been given to patients younger than 1 year of age or older than 9 years of age 
(at the start of the clinical trial).  </p>
<p>The recommended dose of this medicine is based upon your or your child s age, and is given once 
every other week as follows:</p>
<ul>
<li>birth to &lt; 6 months: 100 mg </li>
<li>6 months to &lt; 1 year: 150 mg </li>
<li>1 year to &lt; 2 years: 200 mg (first 4 doses), 300 mg (all other doses) </li>
<li>2 years: 300 mg </li>
</ul>
<p>Your doctor may adjust you or your child s dose or the amount of time the medicine is given if the 
infusion is not tolerated, there is an allergic reaction or there is a possible increase of pressure in the 
brain. </p>
<p>The medicine is slowly pumped through the implanted device. After the medicine has been given, a 
shorter infusion of a solution is given to flush Brineura out of the infusion equipment so that the full 
dose reaches the brain. The medicine and solution will be given over about 2 to 4 hours and 
30 minutes according to your or your child s dose. Your doctor may lower the dose or the speed of the 
infusion based on your response during the treatment. </p>
<p>Your doctor may give you or your child medicines, such as antipyretics to reduce fever or 
antihistamines to treat allergic reactions before each treatment with this medicine to reduce side effects 
that can occur during or shortly after treatment. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Talk to your doctor or nurse immediately if you experience any of the following: </p>
<p>Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>convulsions (seizures) </li>
<li>reactions during or shortly after being given the medicine, such as hives, itching or flushing, 
swollen lips, tongue and/or throat, shortness of breath, hoarseness, turning blue around finger 
tips or lips, low muscle tone, fainting or incontinence. </li>
<li>device-related bacterial infections  </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>severe allergic reaction (anaphylactic reactions). </li>
</ul>
<p>Not known (frequency cannot be estimated from the available data):</p>
<ul>
<li>inflammation of the brain (meningitis) due to device-related infection. </li>
</ul>
<p>This medicine may cause other side effects: </p>
<p>Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>fever </li>
<li>vomiting </li>
<li>feeling irritable  </li>
<li>headache </li>
<li>increased or decreased protein in the brain fluid detected by laboratory monitoring </li>
<li>abnormal results of heart electrical activity (ECG) </li>
<li>increased cells in the spinal fluid detected by laboratory monitoring </li>
<li>device does not function correctly due to a blockage detected during preparation for infusion </li>
<li>
<p>leakage of the device </p>
</li>
<li>
<p>needle issue (infusion needle falls out of implanted device). </p>
</li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>slower heart beat  </li>
<li>rash </li>
<li>hives </li>
<li>device breakage </li>
<li>device site irritation </li>
<li>feeling nervous </li>
<li>disorder of the stomach or intestines. </li>
</ul>
<p>Not known (frequency cannot be estimated from the available data):</p>
<ul>
<li>device is displaced and does not function correctly when preparing for infusion. </li>
</ul>
<p>Reporting of side effects<br />
If you or your child gets any side effects, talk to your doctor. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store brineura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store brineura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date, which is stated on the vials and carton after EXP. The 
expiry date refers to the last day of that month.  </p>
<p>Store upright in a freezer (-25 C to -15 C). Store in the original package, in order to protect from light. 
Transport and distribute frozen (-85 C to -15 C). </p>
<p>Thawed Brineura and flushing solution should be used immediately. This medicine should only be 
withdrawn from the unopened vials immediately prior to use. If immediate use is not possible, 
unopened vials of Brineura or flushing solution should be stored in a refrigerator (2 C - 8 C) and used 
within 24 hours. </p>
<p>Chemical and physical in-use stability has been demonstrated for up to 12 hours at room 
temperature (19 C - 25 C). From a microbiological point of view, open vials or medicinal product 
held in syringes should be used immediately. If not used immediately, in-use storage times and 
conditions prior to use are the responsibility of the user. </p>
<p>Your doctor or pharmacist is responsible for storing Brineura. They are also responsible for disposing 
of any unused Brineura properly. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Brineura contains 
- The active substance is cerliponase alfa. Each vial of Brineura contains 150 mg of cerliponase 
alfa in 5 ml of solution. Each ml of solution for infusion contains 30 mg of cerliponase alfa.<br />
- The other ingredients of Brineura solution for infusion and the flushing solution are: sodium 
phosphate dibasic heptahydrate, sodium dihydrogen phosphate monohydrate, sodium chloride, 
potassium chloride, magnesium chloride hexahydrate, calcium chloride dihydrate and water for 
injections (see section 2  Brineura contains sodium and potassium ). </p>
<p>What Brineura looks like and contents of the pack 
Brineura and the flushing solution are solutions for infusion. The Brineura solution for infusion is 
clear to slightly opalescent, colourless to pale yellow that may occasionally contain thin translucent 
fibres or opaque particles. The flushing solution is clear and colourless.  </p>
<p>Pack size: Each pack contains two vials of Brineura solution for infusion and one vial of flushing 
solution, each containing 5 ml of solution. </p>
<p>Marketing Authorisation Holder and Manufacturer 
BioMarin International Limited 
Shanbally, Ringaskiddy 
County Cork 
Ireland </p>
<p>This leaflet was last revised in   </p>
<p>This medicine has been authorised under  exceptional circumstances . This means that because of the 
rarity of this disease it has been impossible to get complete information on this medicine. </p>
<p>The European Medicines Agency will review any new information on this medicine every year and 
this leaflet will be updated as necessary. </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-3552692c711f8f7419edb391c717f809
InstanceOf: CompositionUvEpi
Title: "Composition for brineura Package Leaflet"
Description:  "Composition for brineura Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp3552692c711f8f7419edb391c717f809)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - brineura"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du eller dit barn får Brineura </li>
<li>Sådan gives Brineura </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What brineura is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What brineura is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brineura indeholder det aktive stof cerliponase alfa, som tilhører en gruppe af lægemidler, der kaldes 
enzymsubstitutionsbehandling. Det anvendes til at behandle patienter med sygdommen 
neuronalceroidlipofuscinosis type 2 (CLN2) også kaldet TPP1-mangel (tripeptidyl peptidase-1). </p>
<p>Mennesker med CLN2-sygdom har ikke et enzym, der hedder TPP1, eller de har for lidt af det, og det 
forårsager en ophobning af stoffer, der hedder lysosomale aflejringer. Hos mennesker med CLN2-
sygdom ophobes disse materialer i visse dele af kroppen, hovedsageligt i hjernen. </p>
<p>Sådan virker Brineura 
Dette lægemiddel erstatter det manglende enzym, TPP1, hvilket mindsker ophobningen af de 
lysosomale aflejringer. Lægemidlet sinker sygdomsudviklingen.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take brineura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take brineura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Brineura 
- hvis du eller dit barn har haft en livstruende allergisk reaktion på cerliponase alfa eller et af de 
øvrige indholdsstoffer i dette lægemiddel (angivet i afsnit 6), og den allergiske reaktion sker 
igen, når cerliponase alfa indgives igen. 
- hvis du eller dit barn har et implanteret dræn for at tømme overskydende væske ud fra hjernen. 
- hvis du eller dit barn har aktuelle tegn på betændelse i forbindelse med anordningen, eller der er 
problemer med anordningen. Lægen kan beslutte at fortsætte behandlingen, når betændelsen 
eller problemerne med anordningen er forsvundet.  </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du eller dit barn får Brineura. 
- Du eller dit barn kan få problemer med den implanterede anordning, der bruges under 
behandlingen med Brineura (se afsnit 4, "Bivirkninger"), herunder infektion eller fejl ved 
anordningen. Hvis du eller dit barn har en infektion, kan det vise sig ved feber, hovedpine, 
nakkestivhed, lysfølsomhed, kvalme, opkastning og ændret sindstilstand. Hvis der er problemer 
med anordningen, kan der opstå hævelse, rødme i hovedbunden, læk af væske fra anordningen 
og udbulning af hovedbunden. Behandlingen kan blive afbrudt, hvis anordningen skal udskiftes, 
eller indtil infektionen går væk. Inden for 4 års anvendelse skal adgangsudstyret muligvis 
udskiftes; dette vil lægen afgøre. Tal med lægen, hvis der er noget ved den implanterede 
anordning, du er i tvivl om. 
- Det er muligt at få livstruende allergiske reaktioner (anafylaktiske reaktioner) ved behandling 
med dette lægemiddel. Lægen overvåger dig eller dit barn for tegn på livstruende allergiske 
reaktioner, såsom nældefeber, kløe eller rødme, hævede læber, tunge og/eller svælg, 
kuldegysninger, hurtigere hjerterytme, kortåndethed, hæshed, blå fingerspidser eller læber, lav 
muskeltonus, besvimelse, diarré eller inkontinens. Søg omgående lægehjælp, hvis disse 
symptomer opstår. 
- Lægen eller sygeplejersken vil måle din eller dit barns puls, blodtryk, vejrtrækningshastighed og 
temperatur inden, under og efter behandlingen. Lægen kan beslutte at foretage yderligere 
kontrol, hvis det er nødvendigt. 
- Lægen eller sygeplejersken vil hver 6. måned tage et EKG for at undersøge, om der er unormal 
elektrisk hjerteaktivitet. Hvis du eller dit barn tidligere har haft problemer med hjertet, vil lægen 
eller sygeplejersken måle hjerteaktiviteten under hver infusion. 
- Lægen sender måske prøver af hjernevæsken til analyse for at undersøge, om der er tegn på 
infektion. 
- Dette lægemiddel er ikke blevet givet til patienter med fremskreden sygdom i starten af 
behandling eller til børn under 1 år gamle. Lægen vil tale med dig, om Brineura i behandlingen 
er rigtig for dig eller dit barn. </p>
<p>Brug af andre lægemidler sammen med Brineura 
Fortæl altid lægen, hvis du eller dit barn tager andre lægemidler, for nylig har taget andre lægemidler 
eller planlægger at tage andre lægemidler. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du får behandling med dette lægemiddel. </p>
<p>Du må ikke modtage behandling med dette lægemiddel under graviditet, medmindre det tydeligt er 
nødvendigt. Det vides ikke, om dette lægemiddel kan skade dit ufødte barn. </p>
<p>Du bør ikke få dette lægemiddel, hvis du ammer. Det vides ikke, om dette lægemiddel udskilles i 
human modermælk. </p>
<p>Det vides ikke, om dette lægemiddel påvirker frugtbarheden for mennesker. </p>
<p>Trafik- og arbejdssikkerhed 
Det vides ikke, om dette lægemiddel påvirker evnen til at føre motorkøretøj eller betjene maskiner. Tal 
med lægen. </p>
<p>Brineura indeholder natrium og kalium 
Dette lægemiddel indeholder 17,4 mg natrium (hoved komponent af madlavnings-/bordsalt) 
pr. hætteglas. Dette svarer til 0,87 % af den anbefalede maximale daglige indtagelse af natrium for en 
voksen. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (39 mg) kalium pr. hætteglas, dvs. det er i det 
væsentlige kaliumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take brineura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take brineura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du eller dit barn skal have en operation for at få implanteret den anordning, som dette lægemiddel skal 
indgives gennem. Anordningen sørger for, at lægemidlet når en bestemt del af hjernen. </p>
<p>Dette lægemiddel indgives af en læge, der ved, hvordan man indgiver medicin som infusion ind i 
hjernevæsken (intracerebroventrikulær anvendelse) på et hospital eller en klinik. </p>
<p>Dette lægemiddel er ikke blevet givet til patienter under 1 år gamle eller over 9 år gamle (ved starten 
af det kliniske forsøg). </p>
<p>Den anbefalede dosis af dette lægemiddel fastlægges ud fra din eller dit barns alder og indgives af en 
læge eller sygeplejerske en gang hver anden uge efter denne doseringsplan:</p>
<ul>
<li>Fødsel til &lt; 6 måneder: 100 mg </li>
<li>6 måneder til &lt; 1 år: 150 mg </li>
<li>1 år til &lt; 2 år: 200 mg (første 4 doser), 300 mg (alle andre doser) </li>
<li>≥ 2 år: 300 mg </li>
</ul>
<p>Lægen kan justere din eller dit barns dosis eller den tid hvori lægemidlet gives, hvis infusionen ikke 
tolereres, der er en allergisk reaktion, eller der er en mulig stigning i trykket i hjernen. </p>
<p>Lægemidlet pumpes langsomt gennem den implanterede anordning. Når lægemidlet er indgivet, følger 
en kortere infusion med en væske for at skylle Brineura ud af infusionsudstyret, så hele dosen når 
hjernen. Lægemidlet og skyllevæsken gives over et tidsrum på ca. 2 til 4 timer og 30 minutter ifølge 
din eller dit barns dosis. Lægen kan nedsætte dosen eller den hastighed, som lægemidlet indgives ved, 
afhængigt af hvordan du eller dit barn reagerer på behandlingen. </p>
<p>Lægen giver muligvis dig eller dit barn anden medicin, såsom feberstillende midler mod feber eller 
antihistaminer mod allergiske reaktioner, inden hver behandling med dette lægemiddel for at mindske 
de bivirkninger, der kan opstå under eller kort efter behandlingen. </p>
<p>Spørg lægen, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Du bør straks tale med lægen eller sygeplejersken, hvis du får en eller flere af følgende bivirkninger: </p>
<p>Meget almindelige bivirkninger (kan påvirke flere end 1 ud af 10 personer):</p>
<ul>
<li>Krampeanfald </li>
<li>Reaktioner under eller kort efter behandlingen, såsom nældefeber, kløe eller rødme, hævede 
læber, tunge og/eller svælg, kortåndethed, hæshed, blå fingerspidser eller læber, lav 
muskeltonus, besvimelse eller inkontinens </li>
<li>Bakteriel infektion i forbindelse med den indlagte anordning  </li>
</ul>
<p>Almindelige bivirkninger (kan påvirke op til 1 ud af 10 personer):</p>
<ul>
<li>Alvorlig allergisk reaktion (anafylaktiske reaktioner) </li>
</ul>
<p>Ikke kendt (hyppighed kan ikke estimeres ud fra forhåndenværende data):</p>
<ul>
<li>Inflammation i hjernen (meningitis), som skyldes udstyrsrelateret infektion </li>
</ul>
<p>Dette lægemiddel kan give andre bivirkninger: </p>
<p>Meget almindelige bivirkninger (kan påvirke flere end 1 ud af 10 personer):</p>
<ul>
<li>Feber </li>
<li>Opkastning </li>
<li>Irritabilitet </li>
<li>Hovedpine </li>
<li>Øget eller mindsket mængde protein i hjernevæsken registreret ved laboratorieovervågning </li>
<li>Unormal elektrisk aktivitet i hjertet målt med EKG </li>
<li>Øget celleantal i spinalvæsken registreret ved laboratorieovervågning </li>
<li>Anordningen fungerer ikke korrekt pga. tilstopning, som registreres ved klargøring til infusion </li>
<li>Lækage af anordningen </li>
<li>Nåleproblem (infusionsnål falder ud af implanteret anordning) </li>
</ul>
<p>Almindelige bivirkninger (kan påvirke op til 1 ud af 10 personer):</p>
<ul>
<li>Langsommere hjerterytme  </li>
<li>Udslæt </li>
<li>Nældefeber </li>
<li>Ødelagt anordning </li>
<li>Irritation på anordningens placering </li>
<li>Nervøsitet </li>
<li>Mave- eller tarmbesvær </li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data):</p>
<ul>
<li>Anordningen forskubbes og fungerer ikke korrekt ved klargøring til infusion </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du eller dit barn oplever bivirkninger, bør du tale med din læge. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store brineura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store brineura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på hætteglassene og æsken efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned.  </p>
<p>Opbevares opretstående i dybfryser (-25 °C til -15 °C). Opbevares i den originale yderpakning for at 
beskytte mod lys. Transporteres og distribueres nedfrosset (-85 °C til -15 °C). </p>
<p>Optøet Brineura og skyllevæske skal anvendes straks. Dette lægemiddel må kun udtages fra de 
uåbnede hætteglas umiddelbart inden anvendelse. Hvis omgående anvendelse ikke er mulig, skal 
uåbnede hætteglas med Brineura eller skyllevæske opbevares i køleskab(2 °C - 8 °C) og anvendes 
inden 24 timer. </p>
<p>Kemisk og fysisk stabilitet ved brug er blevet påvist i op til 12 timer ved stuetemperatur 
(19 °C - 25 °C). Ud fra et mikrobiologisk synspunkt skal åbne hætteglas eller lægemiddelprodukt i 
sprøjter anvendes øjeblikkeligt. Hvis de ikke anvendes straks, er opbevaringstider og -forhold før 
anvendelse brugerens ansvar. </p>
<p>Det er lægens eller apotekspersonalets ansvar at opbevare Brineura. Det er også deres ansvar at 
bortskaffe eventuelt ikke anvendt Brineura på korrekt vis. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brineura indeholder:</p>
<ul>
<li>Aktivt stof: Cerliponase alfa. 1 hætteglas Brineura indeholder 150 mg cerliponase alfa i 5 ml 
infusionsvæske. 1 ml infusionsvæske, opløsning, indeholder 30 mg cerliponase alfa.  </li>
<li>Øvrige indholdsstoffer i Brineura infusionsvæske, opløsning og skyllevæsken: Dibasisk 
natriumfosfat heptahydrat, natriumdihydrogenfosfat monohydrat, natriumchlorid, 
kaliumchlorid, magnesiumchloridhexahydrat, calciumchloriddihydrat og vand til 
injektionsvæske (se afsnit 2, "Brineura indeholder natrium og kalium"). </li>
</ul>
<p>Udseende og pakningsstørrelser 
Brineura og skyllevæsken er infusionsvæsker som opløsninger. Brineura infusionsvæske, opløsning er 
klar til let opaliserende og farveløs til lysegul, som ind imellem kan indeholde tynde, gennemsigtige 
fibre eller uigennemsigtige partikler. Skyllevæsken er klar og farveløs.  </p>
<p>Pakningsstørrelse: Hver pakning indeholder 2 hætteglas med Brineura infusionsvæske, opløsning og 
1 hætteglas med skyllevæske, der hver indeholder 5 ml væske. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
BioMarin International Limited 
Shanbally, Ringaskiddy 
County Cork 
Irland </p>
<p>Denne indlægsseddel blev senest ændret. </p>
<p>Dette lægemiddel er godkendt under "særlige vilkår". Det betyder, at det grundet sygdommens 
sjældenhed ikke har været muligt at opnå fuldstændig dokumentation for lægemidlet. </p>
<p>Det Europæiske Lægemiddelagentur vil hvert år vurdere nye oplysninger om lægemidlet, og denne 
indlægsseddel vil om nødvendigt blive ajourført. </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-3552692c711f8f7419edb391c717f809
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for brineura Package Leaflet for language en"
Description: "ePI document Bundle for brineura Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-3552692c711f8f7419edb391c717f809"
* entry[0].resource = composition-en-3552692c711f8f7419edb391c717f809

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3552692c711f8f7419edb391c717f809"
* entry[=].resource = mp3552692c711f8f7419edb391c717f809
                            
                    
Instance: bundlepackageleaflet-da-3552692c711f8f7419edb391c717f809
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for brineura Package Leaflet for language da"
Description: "ePI document Bundle for brineura Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-3552692c711f8f7419edb391c717f809"
* entry[0].resource = composition-da-3552692c711f8f7419edb391c717f809

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3552692c711f8f7419edb391c717f809"
* entry[=].resource = mp3552692c711f8f7419edb391c717f809
                            
                    



Instance: mp3552692c711f8f7419edb391c717f809
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Brineura 150 mg solution for infusion"
Description: "Brineura 150 mg solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1192/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Brineura 150 mg solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 3552692c711f8f7419edb391c717f809ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "brineura"

* status = #current
* mode = #working

* title = "List of all ePIs associated with brineura"

* subject = Reference(mp3552692c711f8f7419edb391c717f809)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#brineura "brineura"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-3552692c711f8f7419edb391c717f809) // brineura en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-3552692c711f8f7419edb391c717f809) // brineura da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-3552692c711f8f7419edb391c717f809
InstanceOf: List

* insert 3552692c711f8f7419edb391c717f809ListRuleset
    